Lineage Cell Therapeutics, Inc. (LCTX) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — LCTX

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	37.35	35.94	40.46	42.27	47.89	27.75	29.62	43.58	31.47	33.89	15.45	24.75	70.86	78.06	60.81	62.00	56.21
Short-term Investments	13.47	17.44	0.02	0.02	0.02	4.96	8.87	0.05	9.86	12.04	31.36	41.60	1.17	1.88	4.30	6.75	6.15
Accounts Receivable	0.79	0.81	0.13	0.26	0.21	0.41	0.24	0.08	0.43	0.44	--	0.40	0.50	--	--	--	--
Total Current Assets	52.97	56.16	42.26	43.84	49.98	34.40	40.39	45.72	43.48	48.49	49.66	68.51	74.03	81.87	68.34	71.58	64.62
Property, Plant & Equipment	2.52	2.50	2.16	2.26	2.15	2.01	2.02	2.10	4.85	5.31	5.58	4.65	3.87	4.55	4.73	5.01	5.11
Goodwill	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67	10.67
Intangible Assets	31.70	31.70	0.00	0.00	0.00	46.54	46.54	46.54	0.05	0.09	0.12	0.18	0.22	0.25	0.31	46.89	46.92
Total Non-current Assets*	53.25	53.37	47.38	46.96	61.77	62.19	62.41	62.77	62.67	63.20	63.55	62.64	61.90	62.65	62.87	63.18	63.31
Total Assets	106.22	109.53	89.64	90.80	111.75	96.59	102.80	108.48	106.15	111.69	113.21	131.15	135.92	144.52	131.21	134.75	127.93
Accounts Payable	5.39	5.57	4.55	4.45	4.98	4.48	5.02	5.68	5.03	4.68	5.25	9.81	8.68	8.96	6.71	5.35	5.73
Total Current Liabilities	8.02	8.15	9.38	10.76	13.09	13.86	15.28	16.89	15.88	16.05	17.23	22.74	25.09	24.59	8.79	6.77	6.62
Total Non-current Liabilities*	38.41	48.69	59.46	32.93	21.01	17.94	20.65	20.60	23.61	24.38	26.97	30.86	29.33	34.71	2.83	4.39	4.74
Total Liabilities	46.42	56.84	68.84	43.69	34.10	31.80	35.93	37.49	39.49	40.43	44.19	53.60	54.42	59.30	11.62	11.15	11.36
Retained Earnings	(470.33)	(471.81)	(467.85)	(438.07)	(407.60)	(400.19)	(397.16)	(391.40)	(380.08)	(372.97)	(367.74)	(357.02)	(350.95)	(344.18)	(308.10)	(300.28)	(295.49)
Total Stockholder Equity	60.92	53.88	22.04	48.39	79.03	66.19	68.30	72.40	68.12	72.67	70.45	78.95	82.85	86.55	120.71	124.71	117.67

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	1.07	1.73	6.61	3.68	2.77	1.50	2.87	3.78	1.41	1.44	2.09	1.25	2.87	2.12	1.76	2.59	4.15	4.87	0.22	0.29
Cost of Revenue*	--	--	--	--	1.52	0.04	0.15	0.04	0.04	0.10	0.26	0.17	0.13	0.12	0.10	0.24	0.22	0.18	0.20	0.99
Gross Profit	--	--	--	--	1.24	1.47	2.71	3.74	1.36	1.35	1.83	1.08	3.10	2.27	1.81	2.76	4.34	5.06	0.96	1.29
Research & Development	4.77	4.23	8.24	3.27	3.11	3.11	3.42	3.17	2.87	3.01	3.91	3.74	3.87	4.18	4.11	3.59	3.30	2.99	24.78	2.81
Selling, General & Admin	5.22	5.08	4.85	4.19	4.56	4.86	4.40	4.41	4.36	5.00	4.29	4.04	4.25	4.72	4.35	4.42	5.27	8.47	4.42	5.32
Total Operating Expenses	--	--	--	--	7.27	7.97	7.82	7.58	7.23	8.01	8.19	7.78	8.12	8.91	8.45	8.01	8.57	11.46	29.20	8.13
Operating Income	(8.92)	(7.59)	(6.55)	(3.79)	(19.78)	(6.50)	(5.11)	(3.84)	(5.87)	(6.66)	(6.36)	(6.70)	(5.02)	(6.64)	(6.64)	(5.25)	(4.23)	(6.40)	(28.24)	(6.84)
Pretax Income	--	--	--	--	--	--	(3.25)	(3.00)	(5.77)	(6.56)	(4.71)	(7.16)	(5.20)	(6.21)	(6.36)	(5.57)	(6.78)	(7.09)	(28.01)	(8.85)
Tax Provision	--	--	--	--	--	--	0.00	0.00	0.00	0.00	0.00	(1.80)	--	--	0.00	0.54	--	--	--	--
Net Income	1.48	(4.81)	0.85	(29.78)	(30.46)	(4.14)	(3.27)	(3.03)	(5.76)	(6.54)	(4.78)	(7.11)	(5.23)	(4.37)	(6.35)	(6.07)	(6.76)	(7.09)	(28.99)	(7.82)
Basic EPS	0.01	(0.02)	0.00	(0.13)	(0.13)	(0.02)	0.00	(0.02)	(0.03)	(0.04)	(0.02)	(0.04)	(0.03)	(0.03)	(0.03)	(0.04)	(0.04)	(0.04)	--	(0.05)
Diluted EPS	(0.03)	(0.03)	0.00	(0.13)	(0.13)	(0.02)	0.00	(0.02)	(0.03)	(0.04)	(0.02)	(0.04)	(0.03)	(0.03)	--	(0.04)	(0.04)	(0.04)	--	(0.05)

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	(7.24)	(8.08)	(4.88)	(3.62)	(5.54)	(4.89)	(6.35)	(5.79)	(5.18)	(5.78)	(6.02)	(5.04)	(6.27)	(11.24)	(8.30)	(5.48)	(7.06)	21.90	(5.87)	(4.85)
Capital Expenditures	0.11	0.06	0.40	0.01	0.01	0.10	0.37	0.11	0.05	0.04	0.09	0.14	0.26	0.19	(0.02)	0.43	--	--	--	--
Free Cash Flow*	(7.35)	(8.13)	(5.28)	(3.63)	(5.55)	(4.98)	(6.71)	(5.90)	(5.23)	(5.82)	(6.11)	(5.18)	(6.52)	(11.43)	(8.29)	(5.91)	--	--	--	--
Investing Cash Flow	3.96	(2.33)	(15.33)	(0.01)	(0.01)	1.90	2.64	3.89	(8.79)	(0.04)	9.74	2.12	19.16	15.43	(5.10)	(40.91)	(0.10)	(0.05)	(0.15)	(0.07)
Financing Cash Flow	4.47	5.56	20.38	1.83	(0.31)	5.04	21.73	-0.00	0.11	14.02	(0.01)	0.81	5.63	0.00	0.12	0.96	0.03	0.51	0.95	3.72

* Derived from reported values